Qiagen negotiated exclusive, worldwide distribution rights to Celera’s next-generation ResPlex II multiplex assay for the detection of respiratory pathogens. The new assay detects 19 different pathogens and is designed for use with the Luminex LiquiChip 100 and 200 instrument platforms, for which Qiagen is also a partner. The test has yet to be submitted for regulatory approval in the U.S. and Europe.
Home Topics Drug Discovery Qiagen to Distribute Celera’s ResPlex II Multiplex Assay for Respiratory Pathogens
Qiagen to Distribute Celera’s ResPlex II Multiplex Assay for Respiratory Pathogens
Avantor's Inventory Manager and e-commerce channel were integrated into Labguru's lab information management software and electronic lab notebook. [Credit: Westend61/Getty Images]
